Supplementary Materials
Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy
Melissa E. Schechter, Bruno B. Andrade,* Tianyu He, George Haret Richter, Kevin W. Tosh, Benjamin B. Policicchio, Amrit Singh, Kevin D. Raehtz, Virginia Sheikh, Dongying Ma, Egidio Brocca-Cofano, Cristian Apetrei, Russel Tracy, Ruy M. Ribeiro, Alan Sher, Ivo M. B. Francischetti, Ivona Pandrea,* Irini Sereti*
*Corresponding author. Email: bruno.andrade{at}bahia.fiocruz.br (B.B.A.); isereti{at}niaid.nih.gov (I.S.); pandrea{at}pitt.edu (I.P.)
Published 30 August 2017, Sci. Transl. Med. 9, eaam5441 (2017)
DOI: 10.1126/scitranslmed.aam5441
This PDF file includes:
- Materls and Methods
- Fig. S1. Gating strategy used to evaluate monocytes in PBMC.
- Fig. S2. Detailed phenotyping of TF-expressing monocytes.
- Fig. S3. Frequency of TF-expressing monocytes in patients prospectively undergoing ART and its relationship with CRP and D-dimer.
- Fig. S4. Circulating CD14+ monocytes, but not myeloid dendritic cells, express TF in chronically SIV-infected PTMs.
- Fig. S5. Induction of TF expression in the gut of PTMs infected with SIVab.
- Fig. S6. Intracellular cytokine production and TF expression in HIV-infected patients and in SIVab-infected NHPs.
- Fig. S7. Thrombin induces TF expression on CD14high monocytes via PAR-1.
- Fig. S8. Cell viability upon treatment with Ixolaris and/or LPS in vitro.
- Fig. S9. Activated monocytes expressing TF represent a link between coagulation and inflammation.
- Table S1. Characteristics of the NHPs used for the in vitro studies.
- Table S2. Characteristics of HIV-infected individuals included in the crosssectional analysis.
- Table S3. Characteristics of HIV-infected individuals included in the prospective analyses.
- Table S4. List of antibodies used in the flow cytometry experiments in both human and NHP samples.
- Table S5. List of human primers.
- References (59–62)
Other Supplementary Material for this manuscript includes the following:
- Table6 (Microsoft Excel format). Primary data)).